You might also like
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-β) family of proteins. The company is a leader in understanding the role of the TGF-β family, which are master regulators of growth, repair, and maintenance of various tissues. Keros leverages this understanding to develop protein therapeutics with the potential to provide meaningful and disease-modifying benefits to patients.
- Elritercept (KER-050) - Developed for the treatment of low blood cell counts (cytopenias), including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (MDS) and myelofibrosis.
- Cibotercept (KER-012) - Developed for the treatment of pulmonary arterial hypertension (PAH) and cardiovascular disorders.
- KER-065 - Developed for the treatment of neuromuscular diseases and obesity.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Jasbir Seehra ExecutiveBoard | Chief Executive Officer | Board Member of a private life sciences company | Jasbir Seehra has led Keros Therapeutics as CEO since December 2015. He was also appointed Chair of the Board on July 1, 2024 , building on extensive experience in executive and scientific leadership. | View Report → |
Christopher Rovaldi Executive | President and Chief Operating Officer | Christopher Rovaldi is the President and Chief Operating Officer at Keros Therapeutics, serving as President since July 1, 2024 and as Chief Operating Officer since February 2022. He has extensive biotechnology experience, having held senior roles at Acceleron Pharma Inc. and worked as a consultant to biotechnology companies. | ||
Keith Regnante Executive | Chief Financial Officer | Keith Regnante is the Chief Financial Officer at Keros Therapeutics, Inc. since February 2020, and he previously served as CFO at Wave Life Sciences from August 2016 to January 2020 while holding several other financial leadership roles in the pharmaceutical industry. | ||
Yung Chyung Executive | Chief Medical Officer | Dr. Yung Chyung serves as the Chief Medical Officer at Keros Therapeutics since November 1, 2024. He has extensive experience in clinical development from his previous executive roles at Tourmaline Bio, Inc. and Scholar Rock Holding Corporation. |
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
In March 2024, received FDA approval of its product, sotatercept (WINREVAIR), for the treatment of adults with PAH. In August 2024, announced that the European Commission approved sotatercept for the treatment of adults with PAH. All of the other currently-approved therapies for PAH are vasodilators, which are medications that dilate blood vessels. | |
Developing seralutinib for the treatment of PAH. | |
Markets EMFLAZA (deflazacort), an FDA-approved corticosteroid for the treatment of DMD. | |
Markets FDA-approved exon skipping drugs: EXONDYS 51 (eteplirsen), VYONDYS 53 (golodirsen), and AMONDYS 45 (casimersen), which are phosphorodiamidate morpholino oligomers, or PMOs, approved for the treatment of patients with DMD who are amenable to exon 51, exon 53 and exon 45 skipping, respectively. Additionally, in June 2023, announced that the FDA accelerated approval of its product, ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with DMD with a confirmed mutation in the DMD gene. | |
Nippon Shinyaku Co. Ltd. | Markets VILTEPSO (vitolarsen), a PMO approved for the treatment of patients with DMD who are amenable to exon 53 skipping. |
Italfarmaco S.p.A. | In March 2024, announced that the FDA approved Duvyzat (givinostat), a histone deacetylase inhibitor for the treatment of DMD in patients aged six years and older. |
Developing gene therapies to treat DMD. | |
Audentes Therapeutics, Inc. | Developing gene therapies to treat DMD. |
Developing gene therapies to treat DMD. | |
Pursuing gene editing treatments that are in preclinical development for DMD. | |
Santhera Pharmaceuticals | In collaboration with ReveraGen Biopharma, Inc, developing a steroid therapy for DMD. |
Developing product candidates for the treatment of anemia. | |
Astellas Pharma Inc. | Developing product candidates for the treatment of anemia. |
Developing product candidates targeting diseases associated with MDS and myelofibrosis, including chronic anemia. In April 2020, received FDA approval of its product, Reblozyl, for the treatment of anemia failing an erythropoiesis stimulating agent and requiring two or more red blood cell units over eight weeks in adult patients with very low- to intermediate-risk MDS with ring sideroblasts or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. | |
Disc Medicine | Developing product candidates targeting diseases associated with MDS and myelofibrosis, including chronic anemia. |
In June 2024, announced that the FDA approved imetelstat (RYTELO) for the treatment of adult patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents. | |
CTI BioPharma Corp. | In March 2022, received FDA accelerated approval of its product, pacritinib (Vonjo), for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 imes 109/L. |
In September 2023, announced that the FDA approved its product, Ojjaara, for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anemia. | |
MorphoSys AG | Developing a product candidate as a treatment for myelofibrosis. |
Developing an ALK2 inhibitor product candidate for the treatment of myelofibrosis. | |
Developing product candidates that are designed to target the TGF-ß signaling pathways. | |
Developing product candidates that are designed to target the TGF-ß signaling pathways. | |
Developing product candidates that are designed to target the TGF-ß signaling pathways. |
Recent press releases and 8-K filings for KROS.
- ADAR1 Capital Management (holding approximately 13.3% of Keros’ shares) announced plans to withhold votes for directors Dr. Mary Ann Gray and Dr. Alpna Seth at the upcoming annual meeting on June 4, 2025, citing serious concerns over the company's strategic direction.
- The firm criticized the alarming clinical results of drug candidates KER-012 and KER-065 and recommended focusing on KER-050 (elritercept), which it projects could achieve peak sales exceeding $2 billion.
- ADAR1 urged a major restructuring, including reducing headcount by at least 70% and returning excess cash to shareholders, amidst evidence of consistent negative stock performance relative to proxy peers and major indices.
- Net income reached $148.5 million in Q1 2025, a significant turnaround from a net loss in Q1 2024, driven by strong license revenue from Takeda and increased overall revenue.
- Total revenue for the quarter was approximately $211.2 million, with research and development expenses rising to $48.7 million and general and administrative expenses at $10.5 million.
- The company’s cash position improved to $720.5 million as of March 31, 2025, providing a funding runway into 2029.
- Material definitive agreement entered on April 17, 2025, with Pontifax funds, outlining key arrangements including board nominations and associated restrictions ([doc 2][doc 0]).
- Agreement specifies the nomination of board directors Mary Ann Gray, Ran Nussbaum, and Alpna Seth for the 2025 Annual Meeting, ensuring equal support for all nominees ([doc 1][doc 2]).
- The document also includes provisions imposing standstill and non-disparagement obligations to restrict certain shareholder activities until specified conditions are met ([doc 2][doc 3]).
- Board initiates a formal review process to evaluate strategic alternatives—including a potential sale, business combination, continued pipeline investment, or return of excess capital—to maximize stockholder value.
- Adopts a limited-duration stockholder rights plan to protect the process and guard against hostile accumulations during the strategic review.
- KER-065 Phase 1 trial met key objectives for safety, tolerability, pharmacokinetics, and pharmacodynamics, with encouraging biomarker changes supporting its potential in treating Duchenne muscular dystrophy
- Data indicated improvements in whole body bone mineral density, lean muscle mass, and fat mobilization, reinforcing the clinical potential of KER-065
- Regulatory engagement is planned, with a Phase 2 trial proposed for DMD initiation in early Q1 2026, building on the positive Phase 1 outcomes
- Financial Results: Reported a fourth quarter net loss of $46.0 million and a full-year net loss of $187.4 million, with Q4 revenue of $3.0 million and full-year revenue of $3.6 million, driven by increased R&D and general expenses.
- Strong Liquidity: Cash and cash equivalents stood at $559.9 million as of December 31, 2024, and a $200.0 million upfront payment from the Takeda Agreement supports funding operations into 2029.
- Pipeline Progress: Initiated a Phase 1 clinical trial for KER-065 in healthy volunteers, with planned advancement into a Phase 2 trial for neuromuscular diseases and upcoming data from the Phase 2 TROPOS trial evaluating cibotercept.
- Pomerantz LLP is investigating investor claims alleging securities fraud and other unlawful practices by Keros Therapeutics, Inc., including actions by certain officers and directors.
- The investigation follows safety-related actions in the TROPOS trial, which resulted in significant stock price drops on December 12, 2024 and January 15, 2025.
- Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. (KROS) regarding potential securities fraud and unlawful business practices.
- The investigation follows Keros’s announcements on December 12, 2024 and January 15, 2025, when the company halted dosing in its TROPOS trial due to safety concerns related to pericardial effusion adverse events.